Browsing Tag
polycythemia vera
5 posts
Does Priority Review signal a commercial breakthrough for Protagonist Therapeutics, Inc.?
Takeda and Protagonist secure FDA Priority Review for rusfertide in PV. Explore the strategic, financial, and competitive implications now.
Is mutant-selective JAK2 inhibition ready for clinical reality after Prelude Therapeutics’ FDA IND clearance?
Prelude Therapeutics gains FDA IND clearance for PRT12396. Read how mutant-selective JAK2 inhibition could reshape MPN drug development.
Wall Street reacts as Johnson & Johnson circles Protagonist Therapeutics in a potential multibillion-dollar buyout
Explore how Johnson & Johnson’s bid to acquire Protagonist Therapeutics could reshape its immunology and hematology pipeline—details inside.
PharmaEssentia surpasses enrollment goals in clinical trials for hematology candidate BESREMi
PharmaEssentia USA Corporation, a key player in biopharmaceutical innovation and a subsidiary of Taiwan-based PharmaEssentia Corporation, has announced…
Polycythemia vera treatment : Protagonist Therapeutics’ PTG-300 gets FDA ODD
Protagonist Therapeutics has bagged the orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for…